Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Phase 2 Melanoma Drug Data Revealed

By Drug Discovery Trends Editor | June 30, 2011

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

Data was presented by two of Provectus’s Principal Investigators for the Phase 2 melanoma study, Dr. Sanjiv Agarwala, M.D., Chief of Medical Oncology and Hematology at St. Luke’s Hospital and Health Network in Bethlehem, PA, and by Professor Merrick Ross, M.D., of the MD Anderson Cancer Center in Houston, Texas. Dr. Agarwala delivered a presentation entitled “Chemoablation of Metastatic Melanoma with Intralesional PV-10,” at the 7th EADO (European Association of Dermato-Oncology) Conference in Nantes, France, and Dr. Ross’s presentation was entitled “Intralesional Therapy for Systemic Disease: Implications for Success and Failure,” at the HemOnc Today Conference in New York City.

In his presentation, Dr. Agarwala reviewed Phase 2 data on PV-10 and outlined primary design parameters for the Company’s anticipated Phase 3 randomized controlled trial of PV-10, noting that the design is based on guidance obtained in meetings with the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA).

“This was the first time that Phase 2 data and a Phase 3 design outline were widely disseminated to an audience of prospective European investigators who specialize in dermato-oncology and have special interest in injectable therapies,” noted Dr. Agarwala. “I was truly impressed at the level of interest among this important group, some of whom will presumably play a key role in Phase 3, alongside investigators in the U.S. and Australia.”

Dr. Ross provided a comprehensive review of intralesional therapies, starting with BCG (Bacillus Calmette-Guérin) and IL-2 (Interleukin-2) as antecedents to several promising modern intralesional therapies, including PV-10, that are currently undergoing advanced clinical testing. His presentation focused on the role of intralesional therapies for control of both local disease and their possible effect on systemic disease, such as that shown in Phase 2 testing of PV-10.

Dr. Craig Dees, PhD, CEO of Provectus said, “These presentations reinforce the role that PV-10 can play in the management of melanoma, particularly in the large population of patients with locoregional metastatic disease. As we prepare our multi-center, global Phase 3 trial, we take further encouragement from the positive reception of PV-10 in these diverse venues as evidence that the investigational therapy ultimately will be well received by the melanoma community.”

Date: June 29, 2011
Source: Provectus Pharmaceuticals, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50